Navigation Links
LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
Date:6/5/2008

BURLINGTON, N.C. and ROCKVILLE, M.D., June 5 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), one of the world's leading clinical trials and genetic testing laboratories, and Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced an exclusive alliance to develop and commercialize a series of diagnostic tests for genetic markers identified by Vanda in the course of its clinical development of Fanapta(TM) (iloperidone), a novel atypical antipsychotic drug candidate under FDA review for the treatment of schizophrenia. Financial terms of the agreement were not disclosed.

Vanda has identified a series of pharmacogenetic markers during its development of Fanapta(TM), and the company continues its pioneering work in this area. Under the terms of the collaboration, LabCorp will be Vanda's exclusive commercialization partner for tests for genetic markers of the Fanapta(TM) program.

"Working with innovative companies like Vanda to commercialize predictive medicine tests is a critical strategic focus for LabCorp," said Andrew J. Conrad, Ph.D., Chief Scientist and Global Head of Clinical Trials for LabCorp. "This collaboration is an example of our commitment to the advancement of personalized medicine and represents a successful translation of a research based assay into a valuable diagnostic test. This relationship i
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... May 23, 2013 Pusan National University ... private biotherapeutics and contract research company focused on ... cancer, announced today a publication reporting the induction ... the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; ... published in the May 15 th , 2013 ...
(Date:5/23/2013)... Louis, Missouri (PRWEB) May 23, 2013 ... and manufacture of complete thermal systems, recently introduced ... than 90 years of experience in designing and ... complete selection of products to serve diverse customer ... options is featured at the beginning of the ...
(Date:5/22/2013)... iLuv Creative Technology, the premier provider ... mobile lifestyle, announces they are now shipping MultiCharger-X, an ... iPad devices efficiently. Winner of the 2013 internationally recognized ... award, MultiCharger-X is revolutionizing the way businesses, schools, and ... , MultiCharger-X (iAD910) combines the best ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3
... NEW ODOR ELIMINATOR, WHAT ODOR?® Signature pitchman, Billy Mays ENDORSES AND ... ... For The Earth Corp is pleased to announce the launch of a ... marketer Billy Mays., , , , ,Nelson Grist, Founder and CEO of ...
... DIEGO, March 2 BioMed Realty Trust, Inc. (NYSE: ... its executive management will present at the Citi 2009 ... 9:05 a.m. Eastern Standard Time on Wednesday, March 4, ... calling 719.785.5595 and providing the passcode 348395. About BioMed ...
... to Revolutionize Food Processing, Industry,VANCOUVER, ... ("EnWave" or "the Company") today announced that it ... nutraREV(TM) food dehydration equipment to CAL-SAN Enterprises, Ltd. ... blueberry producers. With this sale, EnWave has proven ...
Cached Biology Technology:Billy Mays Endorses New Odor Eliminating Product, What Odor? 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4
(Date:5/23/2013)... for the overall health, development, and academic success ... in ensuring that all students have opportunities to ... of vigorous or moderate-intensity physical activity, says a ... Recent estimates suggest that only about half of ... better health and development. The report recommends ...
(Date:5/23/2013)... succeeded in treating cerebral palsy with autologous cord blood. ... 2.5 year old boy had been in a persistent ... two months after treatment with the cord blood containing ... months, the child learned to speak simple sentences and ... Korean study, dispel the long-held doubts about the effectiveness ...
(Date:5/23/2013)... team reveal the interplay of brain chemicals which help ... Trust and BBSRC. , By changing the way ... abilities. While these changes can affect the strength of ... of that response. , Lead author Alex ... with others, you can make yourself better heard by ...
Breaking Biology News(10 mins):Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... role in the brain's ability to monitor body fat content ... diabetes, according to a new report in the August issue ... particular variants of the protein SH2-B might underlie obesity in ... in cells throughout the body, keeps the brain sensitive to ...
... Institute (BGI) of the Chinese Academy of Sciences (CAS) ... (DCPBP) jointly announce the public release of pig genomic ... of the genomes of five different domestic pig breeds ... the first large scale pig genome sequencing effort, the ...
... methods helped public health officials control and limit the ... virus in 2003 related to the consumption of green ... October 15 issue of The Journal of Infectious Diseases, ... Joseph J. Amon, PhD, MSPH, and colleagues at the ...
Cached Biology News:Weight control protein may yield antiobesity drugs 2Weight control protein may yield antiobesity drugs 3‘Blue Brain?project explores thought at molecular level 2Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance 2
Monoclonal antibodies conjugated with rhodamine...
... lightweight, the Moticam 2300 camera (MC2300) attaches ... eyetube, or trinocular port. Included in the ... Images 2.0ML software offers quick and accurate ... maximize resolution for examination or documentation purposes. ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... BSA-Free Stabilizer is a bovine protein-free ... It is an aqueous solution that ... MOPS buffer (3-(N-Morpholino) propanesulfonic acid), pH ... combination of 0.02% methylisothiazolone and 0.02% ...
Biology Products: